HTG Molecular

The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.

HTG terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments.

The firm received a notice from Nasdaq on Oct. 4 saying its stock had not met the minimum $1-per-share closing price requirement for 30 consecutive business days.

The firm has launched both a public offering of common stock as well as a private placement of warrants, expecting to bring in around $20 million from the transactions.

Revenues from product and product-related services more than doubled to $4.4 million, but collaborative development revenues sank 52 percent to $1.4 million.

While the company's product and product-related revenues rose 54 percent, its collaborative development program revenues fell 78 percent.

Get the latest news from Danaher, HTG Molecular, Bruker, Myriad Genetics, Beckton Dickinson, RenalytixAI, Caris Life Sciences, and Oxford BioDynamics for the week of 5/3/19.